Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

401 - Toxicology, Drug Abuse, Pharmacology > 1-3: Intro, biologics > Flashcards

1-3: Intro, biologics Flashcards

1
Q

study of AEs of chemical, biological, or physical agents on living organisms and the environment

A

toxicology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

substances that cause death, injury, or harm

A

poison

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

chemical/ physical agent/ substance having the characteristics of producing an undesirable or adverse health effect

A

toxic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ability of a toxic agent to cause adverse effects in living organisms

A

toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

chemical/ physical agent/ substance that produces AEs on biological organisms (anthropogenic source), may be chemical or physical (ex- pesticides)- typically man made

A

toxicant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

toxic substance (peptides or proteins) that is produced by biological systems such as plants, animals, fungi, or bacteria. Venoms are toxins produced by a bite or sting- typically natural

A

toxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

anything that can produce an AE (chemical (cocaine), physical (radiation), or biological (venom))

A

toxic agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

organisms that invade and multiply within another organism and produce their effects by biological activity are not classified as toxic agents but biological agents (ex- COVID)

A

biological agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

invading organism excretes a chemical that causes the toxicity (ex- tetanus)

A

biological toxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

T lymphocytes sense foreign peptide fragments presented by

A

antigen presenting cells- MHC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

collection of antibodies from a variety of B cells which are capable of recognizing multiple epitopes on the antigen

A

polyclonal antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

antibody from single B cell which are only capable of recognizing a distinctive epitope

A

monoclonal antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

solid organ transplant prolongs life by

A

~4yrs in most patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the most common solid organ transplant

A

kidney graft

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

describe the graft rejection sequence

A

organ recipient recognizes graft as foreign → activates B and T cells = differentiate/ divide/ generate immune mediators (ex- cytokines) to upregulate the immune system → host immune system attacks the graft → graft destruction → eventual graft rejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

describe the immune process from when the T cell receptor identifies the antigen bound to the MHC on APC

A

cosimulatory signal activated (CD 80/86-CD28) = activates intracellular activities = increases IL2 generation = feedback amplification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what is the purpose of induction therapy

A

enhance initial immunosuppressive effects + delay usage of nephrotoxic agents (Ex- calcineurin inhibitors)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

induction therapy is a _______ course, often ________ with maintenance tx

A

short course
overlapping with maintenance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

2 options for induction therapy

A

depleting agents
immune modulators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

describe depleting agents

A

depletes T lymphocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

describe immune modulators

A

inhibits IL2 associated activation of T lymphocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

High immune risk/ steroid sparing = preferred to use ______ as induction therapy

A

depleting agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

low/ medium immunological risk = preferred to use ________________ as induction tx

A

immune modulators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

rank the induction agents from low to high risk

A

no induction < basiliximab < alemtuzumab < antithymocyte globulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
describe 3 cases where there would be lower risk of rejecting transplant
zero HLA mismatch, live donor, caucasian, lower panel reactive antibody, absence of donor specific antibody, blood group compatibility, immediate graft function, short cold ischemia time, first transplant
26
describe 3 cases where there would be higher risk of rejecting transplant
more HLA mismatches, younger recipient + older donor age, african-american ethnicity, high panel reactive antibody, presence of donor specific antibody, blood group incompatibility, delayed onset of graft function, long cold ischemia time, retransplant
27
what is antithymocyte globulin
purified gamma globulin from rabbits or horses immunized with human thymocytes
28
ATG is
equine
29
rATG is
rabbit
30
rabbit ATG is ____ immunogenic, ______ potent compared to equine
less immunogenic, more potent
31
agglutination og ATG on as cellular surface results in
complement induction + cell mediated cytotoxicity to phagocytosis by macrophages + necrosis/ apoptosis
32
ant thymocyte globulin binds to
T cell surface receptors
33
T or F: antithymocyte globulins can affect B cells or other leukocytes
T
34
antithymocyte globulin can only be adminsitered
IV
35
ATG distribution
binds to circulating lymphocytes, granulocytes, platelets = poor tissue distribution
36
ATG elimination
very little urinary excretion, no typical phase 1 or 2 metabolism
37
PK interactions against ATG
minimal due to lack of renal excretion + conventional phase 1/2 metabolism
38
how is ATG metabolized
proteolysis in the liver +/- reticuloendothelial systems endocytosis + pinocytosis and degradation in lysosomes
39
MOA of serum sickness to ATG
formation and deposition of antibody-ATG complex in tissues = arthralgia + painful joints, ↓ LT graft survival,
40
common infusion related SEs
chills/ fever/ itching/ erythema
41
how to tx common ATG infusionr eactions
prophylactic antihistamine, antipyretics (ex- APAP), slow infusion (4-6hrs)
42
how tto avoid phlebitis from ATG
infuse ATG through central vein
43
how to tx ATG anaphylaxis
stop ATG inf + admin epi, steroids, do not restart
44
how to tx ATG hemolysis
transfusion, pharmtx (eg mannitol to ↓ osmotic swelling of RBCs), hold ATG PRN
45
describe thrombocytopenia as a SE to ATG tx + treatment
transient in kidney transplant pts → platelet count usually return to normal w/out stopping ATG, may req platelet transfusion in resistant cases
46
how to treat respiratory distress from ATG
possible sign of anaphylaxis → can hold ATG, admin antihistamine, epi, corticosteroids
47
chest, flank, back pain to ATF infusion is possibly a sx of
anaphylaxis
48
persistent hypotension from ATG infusion is a possible sx of
anaphylaxis
49
how to tx persistent hypotension from ATG
possible sx of anaphylaxis → stop ATG inf + admin epi, steroids, do no restart ATG, pressors PRN
50
monoclonal antibodies ADME
same as ATG
51
OKT3 (muromonab) is a
depleting agent
52
alemtuzumab is a
depleting agent
53
OKT3 MOA
murine monoclonal antibody, binds to CD3 on the T receptor complex on the surface of T lymphocytes, inactivates T cells = eventual phagocytosis
54
OKT3 indication
solid organ transplants
55
alemtuzumab indication
off label for solid organ transplant for induction + tx of acute rejection
56
alemtuzumab MOA
humanized monoclonal antibody agent against CD52 surface antigen (T and B lymphocytes, macrophages, monocytes, eosinophils), binding to CD52 = antibody dependent lysis = T and B cell removal from various tissues = complete lymphocyte depletion
57
basilizimab indication
induction tx in kidney transplant allows delayed initiation or low dose calcineurin inhibitor
58
basiliximab MOA
chimeric monoclonal antibody which binds competitively to the alpha chain on the CD25 protein (IL2 receptor) on activated T lymphocytes = prevents IL2 mediated T cell activation/ proliferation, immunomodulatory, non depleting
59
belatacept indication
alt to calcineurin inhibitors fro prophylaxis of organ rejection in kidney graft recipients in conjunction wiht basiliximab induction, mycophenolate mofetil, and steroids first MAB maintenance tx in organ transplant
60
belatacept MOA
blocks T cell costimulation inhibitor (binds CD80/86 on APC = reduces interactions and activation = T cell apoptosis)
61
belatacept must be used in conjunction with
basilizimab, mycophenolate mofetil, and steroids
62
which biologic sees post transplant lymphoproliferative disorder in Epstein- Barr virus seronegative patients
belatacept
63
belatacept has a modified ____ segment connected to the extracellular domain of human ______ with ___ mutations to enhance bindign to CD80 /86
modified Fc segment CTLA4 2 mutations
64
leukopenia is more common with _________ agents
lymphocyte depleting agents
65
leukopenia would be more expected with 1. OKT3 2. belataceptt 3. mycophenolate mofetil 4. steroids
1
66
there is a higher incidence of cytomegalovirus infection with
depleting agents
67
rATGs are associated with 1. melanoma 2. nonhodkin's lymphoma 3. colorectal cancer 4. kidney disease
1

401 - Toxicology, Drug Abuse, Pharmacology (32 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions